Questões de Concurso Sobre interpretação de texto | reading comprehension em inglês

Foram encontradas 13.189 questões

Q4322454 Inglês
According to their use in the text, the expressions “heists” (l. 08), “stolen to order” (l. 10), and “heinous” (l. 26) mean, respectively:
Alternativas
Q4322453 Inglês
According to the text, the expression “go on to become” (l. 16-17) indicates that Antonello da Messina
Alternativas
Q4322452 Inglês
Analyze the statements below according to the text:

I. The San Gregorio Polyptych was commissioned for a monastery and depicts religious figures and angels.
II. The double-sided panel was painted in 1473, the same year in which the San Gregorio Polyptych was painted.
III. Investigators suspect that the theft was commissioned by criminals operating in the black market for art.

Which ones are correct?
Alternativas
Q4322451 Inglês
Analyze the statements below about the text and mark T, if true, or F, if false.

( ) The Madonna with Child and Christ in Pietà was removed from inside a protected display case.
( ) The small size of the double-sided panel suggests that it was originally used for personal religious practice.
( ) The investigators know the identities of the individuals who planned the robbery.
( ) The mayor stated that the theft represented an offense against the city’s history and people.

The correct order of filling in the parentheses, from top to bottom, is: 
Alternativas
Q4322450 Inglês
Mark the correct statement about the text. 
Alternativas
Q4320991 Inglês
Read the excerpt below from Moby-Dick by Herman Melville:
"Chief among these motives was the overwhelming idea of the great whale himself. Such a portentous and mysterious monster roused all my curiosity. Then the wild and distant seas where he rolled his island bulk; the undeliverable, nameless perils of the whale; these, with all the attending marvels of a thousand Patagonian sights and sounds, helped to sway me to my wish."
According to the excerpt, which factor most strongly influenced Ishmael's decision to undertake a whaling voyage?
Alternativas
Q4320990 Inglês
Read the excerpt below from Moby-Dick by Herman Melville:
"Why is almost every robust healthy boy with a robust healthy soul in him, at some time or other crazy to go to sea? Why upon your first voyage as a passenger, did you yourself feel such a mystical vibration, when first told that you and your ship were now out of sight of land?"
Considering the narrator's argument in the excerpt, what idea is being emphasized?
Alternativas
Q4320989 Inglês
Read the excerpt below from Moby-Dick by Herman Melville:
"Call me Ishmael. Some years ago—never mind how long precisely—having little or no money in my purse, and nothing particular to interest me on shore, I thought I would sail about a little and see the watery part of the world."
Based on the excerpt, what can be inferred about Ishmael's motivation for going to sea? 
Alternativas
Q4320988 Inglês
Read the excerpt below from Moby-Dick by Herman Melville:
"Who-e debel you?"—he at last said—"you no speak-e, dam-me, I kill-e."
[...]
"Don't be afraid now," said he, grinning again. "Queequeg here wouldn't harm a hair of your head."
[...]
"Me sabbee plenty," grunted Queequeg, puffing away at his pipe and sitting up in bed.
Read the statements below carefully:

I.Queequeg's speech demonstrates a limited command of English grammar and vocabulary.

II.The landlord's statement "Don't be afraid now" performs the social function of reassurance.

III.The expression "wouldn't harm a hair of your head" is used to communicate that Queequeg poses no threat to Ishmael.

IV.The phrase "Me sabbee plenty" illustrates a standard grammatical structure commonly found in formal English.

V.The interaction reveals an initial communication barrier between the characters.

Which statements are correct according to the excerpt?
Alternativas
Q4320984 Inglês
Read the excerpt below from Moby-Dick by Herman Melville:
"I told him that I never liked to sleep two in a bed; that if I should ever do so, it would depend upon who the harpooneer might be, and that if he really had no other place for me, and the harpooneer was not decidedly objectionable, why rather than wander further about a strange town on so bitter a night, I would put up with the half of any decent man's blanket."
"I thought so. All right; take a seat. Supper?—you want supper? Supper 'll be ready directly."


Considering the interaction between Ishmael and the innkeeper, identify the alternative that best describes the primary social function performed by the innkeeper's utterances.
Alternativas
Q4313264 Inglês
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
The article presents Lilly's acquisition of AtaiBeckley as part of a broader corporate strategy. Based on the information provided, the acquisition may be interpreted as an attempt to: 
Alternativas
Q4313263 Inglês
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
A teacher uses the article to discuss how pharmaceutical research, regulation, investment and public communication interact across national borders. The teacher wants to avoid turning the lesson into either commercial promotion or an unsupported debate about medical treatment. Register T for true statements and F for false statements.
(__) Students may compare how the article distinguishes clinical evidence, regulatory decisions and market expectations.
(__) The lesson may examine how international news circulates through English and influences access to scientific and economic information.
(__) Students should evaluate the therapeutic effectiveness of BPL-003 according to their personal experiences with mental-health treatments.
(__) The teacher may require students to distinguish information reported in the article from conclusions not supported by the text.
Mark the alternative that presents the CORRECT sequence.
Alternativas
Q4313262 Inglês
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
Read the excerpt:
"Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials."
Consider the statements:
I. The modal verb could expresses a projected commercial possibility rather than a guaranteed result.
II. The clause introduced by if establishes a condition for the estimated sales performance.
III. The simple present form succeeds refers to a habitual event repeatedly observed in previous trials.
Mark the alternative that presents only the CORRECT statements.
Alternativas
Q4313261 Inglês
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
A teacher prepares an audio adaptation of the article and asks students to identify the difference between confirmed information and market projections. Before listening, the teacher provides the categories confirmed transaction, clinical expectation, and financial estimate. Which procedure most effectively develops the intended listening skill? 
Alternativas
Q4313260 Inglês
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
After reading the article, students compare the headline, financial projections, quoted analysts and descriptions of clinical development. They then produce a short English-language briefing distinguishing facts, forecasts and corporate interests.
Consider the assertions:
I. The activity is compatible with a language-education approach that treats English as a means of accessing and critically examining international information.
BECAUSE
II. Students must analyse how linguistic choices and source positions influence the representation of a contemporary event.
Mark the CORRECT alternative.
Alternativas
Q4309786 Inglês

Read the lyrics’ song Dai Dai, by Shakira (Feat. Burna Boy), to answer question


[…]

You knew from the day

you were born

That here in this place you belong

You've been this brave all along

What broke you once made you strong (strong)


Dai, dai, ikou, dale, allez, let's go 


Dai, dai, ikou, dale, allez, let's go (ow) 


Come follow your desire

Where there's a will, there's a way 


You are the owner of that fire


No one can take it away


Sweat and blood to write your story


That is how you paved the way


You're about to reach the glory


Only one step away

All the highs and lows

All the tears and the pain

You been there through it all, 

been through it all

Just do it again

Now you got to believe (I believe)


 […]


(Available at: https://www.letras.mus.br/shakira/dai-dai-feat-burna-boy/)

Based on the song Dai dai, by Shakira, match the underlined words to their closest meaning in its context and choose the correct alternative.


UNDERLINED WORDS


1. belong

2. brave

3. desire

4. take it away

5. glory 



MEANING


A. To feel comfortable or accepted in a place;

B. To remove or deprive someone of something;

C. Showing courage in the face of difficulty;

D. A strong wish or want for something;

E. Great honor, praise, or success;

Alternativas
Q4309785 Inglês

Read the selection bellow to answer question


Digital texts are unique in that they can be broadcast to people as close as the same classroom and as far away as the other side of the world. This attribute brings with it great responsibility, requiring one to recognize the norms of engaging with people of diverse background experiences, cultures, religions, and ideologies. How we interpret what we read on the inter net, for instance, is grounded in our own beliefs and unerstandings of the world.


(Available at: McDonald, Maureen; Boulden, Lauren; Karchmer-Klein, Rachel. Next-level digital tools and teaching. New York: Teachers College, Columbia University, 2022, p. 15). 

According to the text, why does the widespread reach of digital texts require users to act responsibly?
Alternativas
Q4309780 Inglês

Answer question based on the paragraph bellow:


[The] centrality of emotion in identity may seem to clash with a compelling argument that identity is a consciousness of one’s memories – that is, one’s history – in some organized pattern, often a continuous narrative... At one level, it is indispu table that a sense of one’s own identity is constructed from narrative memory.... However, we believe that we are arguing about a motivational process that underlies the very construction of such memories and the motivation for their construc tion. If people organize their thoughts, memories, and future hopes around happy events, it would be circularly the case that they are most them selves when this organization functions well and should have a sense of not being them selves if it does not function. Moreover, happy people should use particular strategies for thought (including memory construction) that are somewhat different from those of people who feel most themselves when they are excited or exhilarated.



(Available at: Haviland-Jones JM, Kahlbaugh P (2004) Emotion and identity. In: Lewis M, Haviland-Jones JM (eds) Handbook of emotions, 3rd edn. The Guilford Press, New York, pp 293–305) 

Based on the text, judge the following items as false (F) or true (T):

( ) Personal identity is constructed, at least in part, from narrative memory.
( ) The authors argue that motivational processes influence the construction of memories. 
( ) Happy people and people who feel most themselves when excited necessarily use the same thinking strategies. 
( ) The text suggests that the way memories and future expectations are organized can influence an individual's percep tion of their own identity.

The statements are, respectively: 
Alternativas
Q4309777 Inglês
In regard to Rachel's repeated assertion, "Not mine, not mine, not mine," together with her inability to defend herself effectively, it mainly suggests that 
Alternativas
Q4302803 Inglês
TEXT 2

Global Englishes in Language Education

Global Englishes in language education encompasses the study and teaching of English as a pluricentric, international means of communication rather than a single standard variety. This field recognises the multiplicity of English norms around the world and seeks pedagogical approaches that validate diverse accents, dialects and communicative practices. Recent scholarship emphasises critical awareness of power dynamics in language use, challenges the supremacy of native-speaker models and promotes curricula that equip learners to navigate intercultural encounters. Innovations span bottom-up curriculum design, translanguaging and digital technologies, all underpinned by partnerships between researchers and practitioners. The ultimate aim is to prepare both teachers and students for inclusive, intelligible and context-sensitive use of English in global settings.

Content extracted and adapted from: https://www.nature.com/natureindex/topics/l4/global-englishes-in-language-education
In the sentence “Englishes in language education encompasses the study and teaching of English as a pluricentric, international means of communication rather than a single standard variety”, the expression “rather than” establishes a relationship of:
Alternativas
Respostas
321: E
322: B
323: C
324: D
325: A
326: B
327: D
328: C
329: B
330: A
331: D
332: B
333: C
334: D
335: A
336: D
337: D
338: B
339: A
340: B